NASDAQ:SCNX Scienture (SCNX) Stock Price, News & Analysis $0.79 +0.01 (+1.10%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$0.78 -0.01 (-0.72%) As of 10/8/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Scienture Stock (NASDAQ:SCNX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Scienture alerts:Sign Up Key Stats Today's Range$0.75▼$0.8150-Day Range$0.78▼$2.3952-Week Range$0.69▼$9.55Volume286,300 shsAverage Volume432,532 shsMarket Capitalization$16.34 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL. Read More Scienture Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks22nd Percentile Overall ScoreSCNX MarketRank™: Scienture scored higher than 22% of companies evaluated by MarketBeat, and ranked 841st out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Scienture.Read more about Scienture's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioScienture has a P/B Ratio of 0.09. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Scienture's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.41% of the float of Scienture has been sold short.Short Interest Ratio / Days to CoverScienture has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Scienture has recently increased by 64.04%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldScienture does not currently pay a dividend.Dividend GrowthScienture does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.41% of the float of Scienture has been sold short.Short Interest Ratio / Days to CoverScienture has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Scienture has recently increased by 64.04%, indicating that investor sentiment is decreasing significantly. News and Social Media3.3 / 5News Sentiment0.93 News SentimentScienture has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Scienture this week, compared to 1 article on an average week.MarketBeat Follows2 people have added Scienture to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Scienture insiders have not sold or bought any company stock.Percentage Held by Insiders49.70% of the stock of Scienture is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 5.68% of the stock of Scienture is held by institutions.Read more about Scienture's insider trading history. Receive SCNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Scienture and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SCNX Stock News HeadlinesScienture announces repayment, conversion of outstanding debenturesOctober 8 at 3:48 PM | msn.comSCIENTURE Holdings Announces Full Repayment and Conversion of Outstanding Debentures, Strengthening Balance SheetOctober 8 at 3:48 PM | markets.businessinsider.comGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real opportunity isn’t in coins or bullion. In every major gold rally of the past 50 years, there’s been another investment that has delivered dramatically higher returns. | Weiss Ratings (Ad)Scienture Holdings Amends Bylaws for Quorum ChangeOctober 7 at 4:18 PM | msn.comScienture Holdings Amends Convertible Debentures AgreementOctober 3, 2025 | tipranks.comScienture (NASDAQ:SCNX) Trading Down 0.9% - Here's What HappenedOctober 3, 2025 | americanbankingnews.comSCIENTURE Secures Multiple Commercial GPO Agreements, Expanding U.S. Market Access for Arbli™ (losartan potassium) to more than 2500 Healthcare InstitutionsOctober 1, 2025 | finance.yahoo.comScienture Holdings, Inc. Secures GPO Agreements for Arbli™ Oral Suspension, Expanding Access to U.S. Institutional MarketOctober 1, 2025 | quiverquant.comQSee More Headlines SCNX Stock Analysis - Frequently Asked Questions How have SCNX shares performed this year? Scienture's stock was trading at $6.05 at the start of the year. Since then, SCNX stock has decreased by 87.0% and is now trading at $0.7877. How were Scienture's earnings last quarter? Scienture Holdings, Inc. (NASDAQ:SCNX) released its quarterly earnings results on Tuesday, August, 12th. The company reported ($0.48) earnings per share (EPS) for the quarter. Scienture had a negative trailing twelve-month return on equity of 24.47% and a negative net margin of 10,364.22%. How do I buy shares of Scienture? Shares of SCNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Scienture own? Based on aggregate information from My MarketBeat watchlists, some other companies that Scienture investors own include Cogent Communications (CCOI), Cavco Industries (CVCO), Liberty Broadband (LBRDK), Liberty Global (LBTYB), PayPal (PYPL), Roku (ROKU) and Arch Capital Group (ACGL). Company Calendar Last Earnings8/12/2025Today10/09/2025Next Earnings (Estimated)11/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryWholesale Current SymbolNASDAQ:SCNX CIK1382574 Webwww.trxadehealth.com Phone(800) 261-0281Fax800-265-6932EmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$9.07 million Net Margins-10,364.22% Pretax Margin-15,853.78% Return on Equity-24.47% Return on Assets-19.30% Debt Debt-to-Equity Ratio0.02 Current Ratio0.11 Quick Ratio0.11 Sales & Book Value Annual Sales$140 thousand Price / Sales116.75 Cash FlowN/A Price / Cash FlowN/A Book Value$9.04 per share Price / Book0.09Miscellaneous Outstanding Shares20,750,000Free Float10,438,000Market Cap$16.34 million OptionableN/A Beta3.11 The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:SCNX) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scienture Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Scienture With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.